Supported by an educational grant from Takeda

Click on the link to complete the pre-assessment questions before the session begins: https://www.mlieducation.org/soho-2025-session-v-chronic-myeloid-leukemia-pre-assessment/

SESSION V: CHRONIC MYELOID LEUKEMIA

Session Chairs: Delphine Rea, MD, PhD and Kendra Sweet, MD

Evolving Algorithms Based on New Drug Approvals – What Have We Gained | Jorge E. Cortés, MD | Georgia Cancer Center, Augusta, Georgia, USA

Co-Targeting in CML | Mhairi Copland, MBChB, PhD | University of Glasgow, Glasgow, United Kingdom

Debate – Is Targeting BCR::AB1 Alone Sufficient? Yes | Michael Deininger, MD, PhD | University of Michigan, Ann Arbor, Michigan, USA

Is Targeting BCR::AB1 Alone Sufficient? | Timothy P. Hughes, MD, MBBS | South Australian Health and Medical Research Institute, Adelaide, Australia

Oral Abstract | CML-575: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia | Michael J. Mauro, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA